FDA warns Insightra Medical over unapproved IABP catheter claims and missed adverse-event reports.
What happened
FDA inspected Insightra Medical's Clarksville, TN facility from January 21 to January 27, 2025. FDA found that the firm marketed its IABP Catheter Kit with added pump-console compatibility claims and with septic shock/pulsatile flow indications without the required new 510(k) clearance or premarket approval (PMA). FDA also found that the firm's Medical Device Reporting (MDR) procedure was a draft without an effective date and did not define serious injury, and that the firm did not submit required reports for balloon-rupture complaints.
What FDA found
The firm listed the Cardiosave IABP Hybrid and AutoCat 3 as compatible in labeling and on its website without submitting a new 510(k) (premarket notification) for that change.
21 CFR 807.81(a)(3)(ii); section 510(k) of the Act, 21 U.S.C. § 360(k)The firm continued to market the IABP Catheter Kit for septic shock and pulsatile flow generation without a PMA (premarket approval) or PDP notice, or a revised 510(k).
Section 501(f)(1)(A), 21 U.S.C. § 351(f)(1)(A); section 515(b), 21 U.S.C. § 360e(b)The firm's Medical Device Reporting (MDR) procedure was an undated draft with no effective date and did not define 'serious injury' or ensure timely identification and evaluation of reportable events.
21 CFR 803.17The firm did not submit 30-day MDR reports for CMP-36, a balloon rupture tied to serious injury, or CMP-44, a balloon-rupture malfunction that could recur and cause serious injury.
21 CFR 803.50(a)(1); 21 CFR 803.50(a)(2)CAPA (corrective and preventive action) records were incomplete, effectiveness checks were not adequate, and no CAPA was opened for ongoing Double Pump leaks or a broken IABP catheter lumen.
21 CFR 820.100(b)Complaint files lacked MDR decision trees, were entered late, and did not include complete information or follow-up attempts for meaningful investigation.
21 CFR 820.198(a)
What FDA wants
FDA tells the firm to correct the cited violations and address them in its response to the warning letter. The provided letter text does not state a response deadline.
Who should pay attention
- hospitals and clinicians using IABP catheter kits
- distributors and brands selling Insightra devices
- quality teams at device manufacturers with MDR and CAPA duties
This is a summary. Read the original letter on fda.gov.